Taking the battle to Congress. The brand name companies are also looking at a third front, the US Congress. They re talking to lawmakers about the need to strengthen patent protection. They say they need additional patent-protected revenue because that income makes it possible to bring important new products to the market. Research-based companies say sophisticated technologies have made the cost of drug research astronomical.
Patents are the lifeblood of our industry.
Ironically, many of the brand name companies have responded to the demand for generics by creating generic products of their own, but their financial success has been mixed. Given the fact that there is an enormous amount of money at stake for both sides, the battle is likely to continue in state legislatures, before the FDA, and in Congress.